MacroGenics Statistics
Total Valuation
MacroGenics has a market cap or net worth of $140.60 million. The enterprise value is -$112.22 million.
| Market Cap | 140.60M |
| Enterprise Value | -112.22M |
Important Dates
The last earnings date was Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MacroGenics has 63.91 million shares outstanding. The number of shares has increased by 0.77% in one year.
| Current Share Class | 63.91M |
| Shares Outstanding | 63.91M |
| Shares Change (YoY) | +0.77% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 3.58% |
| Owned by Institutions (%) | 72.22% |
| Float | 56.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.00 |
| Forward PS | 1.98 |
| PB Ratio | 5.59 |
| P/TBV Ratio | 5.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.75, with a Debt / Equity ratio of 1.39.
| Current Ratio | 2.75 |
| Quick Ratio | 2.70 |
| Debt / Equity | 1.39 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.90 |
Financial Efficiency
Return on equity (ROE) is -284.54% and return on invested capital (ROIC) is -52.39%.
| Return on Equity (ROE) | -284.54% |
| Return on Assets (ROA) | -14.58% |
| Return on Invested Capital (ROIC) | -52.39% |
| Return on Capital Employed (ROCE) | -32.51% |
| Weighted Average Cost of Capital (WACC) | 17.18% |
| Revenue Per Employee | $480,563 |
| Profits Per Employee | -$175,734 |
| Employee Count | 293 |
| Asset Turnover | 0.48 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -777,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +49.66% in the last 52 weeks. The beta is 1.32, so MacroGenics's price volatility has been higher than the market average.
| Beta (5Y) | 1.32 |
| 52-Week Price Change | +49.66% |
| 50-Day Moving Average | 3.33 |
| 200-Day Moving Average | 3.44 |
| Relative Strength Index (RSI) | 31.90 |
| Average Volume (20 Days) | 1,084,474 |
Short Selling Information
The latest short interest is 4.95 million, so 7.74% of the outstanding shares have been sold short.
| Short Interest | 4.95M |
| Short Previous Month | 5.06M |
| Short % of Shares Out | 7.74% |
| Short % of Float | 8.74% |
| Short Ratio (days to cover) | 5.23 |
Income Statement
In the last 12 months, MacroGenics had revenue of $140.81 million and -$51.49 million in losses. Loss per share was -$0.81.
| Revenue | 140.81M |
| Gross Profit | -33.54M |
| Operating Income | -68.75M |
| Pretax Income | -131.88M |
| Net Income | -51.49M |
| EBITDA | -64.45M |
| EBIT | -68.75M |
| Loss Per Share | -$0.81 |
Balance Sheet
The company has $287.68 million in cash and $34.86 million in debt, with a net cash position of $252.82 million or $3.96 per share.
| Cash & Cash Equivalents | 287.68M |
| Total Debt | 34.86M |
| Net Cash | 252.82M |
| Net Cash Per Share | $3.96 |
| Equity (Book Value) | 25.15M |
| Book Value Per Share | 0.39 |
| Working Capital | 187.85M |
Cash Flow
In the last 12 months, operating cash flow was -$39.87 million and capital expenditures -$1.47 million, giving a free cash flow of -$41.34 million.
| Operating Cash Flow | -39.87M |
| Capital Expenditures | -1.47M |
| Depreciation & Amortization | 4.30M |
| Net Borrowing | n/a |
| Free Cash Flow | -41.34M |
| FCF Per Share | -$0.65 |
Margins
Gross margin is -23.82%, with operating and profit margins of -48.83% and -36.57%.
| Gross Margin | -23.82% |
| Operating Margin | -48.83% |
| Pretax Margin | -93.66% |
| Profit Margin | -36.57% |
| EBITDA Margin | -45.77% |
| EBIT Margin | -48.83% |
| FCF Margin | n/a |
Dividends & Yields
MacroGenics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.77% |
| Shareholder Yield | n/a |
| Earnings Yield | -36.85% |
| FCF Yield | -29.40% |
Analyst Forecast
The average price target for MacroGenics is $8.00, which is 263.64% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.00 |
| Price Target Difference | 263.64% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | -11.45% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MacroGenics has an Altman Z-Score of -4.82 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.82 |
| Piotroski F-Score | 3 |